Synlogic, Inc. (SYBX)
After hours:
| Previous close | 1.9100 |
| Open | 1.9100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.8700 - 1.9100 |
| 52-week range | 0.2340 - 5.7080 |
| Volume | |
| Avg. volume | 138,469 |
| Market cap | 21.78M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.8100 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.00 |
ZacksSynlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireSynlogic Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company recently announced the decision to discontinue Synpheny-3, its pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria (PKU) and evaluate strategic options for the Company. Fourth Quarter 202
- GlobeNewswire
Synlogic Adopts Limited Duration Stockholders Rights Plan
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review processCAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the “Board”) has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right
